Avanafil
Drug100 mg
Other names: TA-1790, Stendra
NCT Number: NCT01768676
The purpose of this study is to determine whether avanafil will affect different aspects of sperm production.
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 4
Research Facility, Huntsville, Alabama, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
100 mg
Other names: TA-1790, Stendra
Time frame: Baseline to Week 26
Subjects provided 2 semen samples at each visit 2 to 12 days apart. The average value is used as the visit result.
Time frame: baseline to week 26
Time frame: baseline to week 26
Sperm motility was based upon the WHO grading scale: grade A, B, or C.
Time frame: baseline to week 26
Time frame: baseline to week 26
VIVUS LLC
Industry
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of the Effect of Avanafil (STENDRA™) on Spermatogenesis in Healthy Adult Males and Adult Males With Mild Erectile Dysfunction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07715448
Benign Prostatic Hyperplasia, Ejaculatory Dysfunction
Banī Suwayf, Beni Suef Governorate, Egypt
View Trial DetailsNCT06805513
Erectile Dysfunction, Genital Diseases
Salt Lake City, Utah, United States
View Trial DetailsNCT07692867
Erectile Dysfunction, Genital Diseases
Beijing, China
View Trial DetailsNCT07460167
Erectile Dysfunction, Genital Diseases
Qina, Egypt
View Trial Details